Overview
PT-141 (bremelanotide) is an FDA-approved peptide therapy developed from the melanocortin system, derived originally from Melanotan II. During early Melanotan II clinical trials at the University of Arizona, 9 out of 10 male volunteers experienced spontaneous erections, prompting targeted development of a compound specifically for sexual dysfunction. Unlike PDE-5 inhibitors (Viagra, Cialis), PT-141 acts centrally on the nervous system rather than the vascular system, making it effective for both men and women.
Mechanism of Action
PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, directly stimulating neural pathways linked to sexual arousal and desire. This triggers dopamine release and nitric oxide production in key brain areas governing sexual behavior. The central nervous system mechanism is distinct from vascular-acting ED medications, allowing PT-141 to address both desire and arousal components simultaneously. It received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Potential Benefits
- FDA-approved for hypoactive sexual desire disorder (HSDD) in women
- Increases sexual desire and arousal in both men and women
- Acts on central nervous system rather than vascular system
- Effective for individuals who do not respond to PDE-5 inhibitors
- Improves scores on Female Sexual Function Index (FSFI)
- Reduces Female Sexual Distress Scale (FSDS) scores
- Onset of action within 45-90 minutes
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 0.5-2 mg/dose as needed |
| Beginner | 0.5-1 mg (30-60 min before sexual activity) |
| Intermediate | 1-1.75 mg as needed |
| Advanced | 2 mg as needed (FDA-approved max dose) |
| Cycle Duration | As needed; not intended for continuous daily use |
| Cycle Off | No formal cycling required; use as needed |
FDA-approved as Vyleesi at 1.75 mg subcutaneous. Duration of action 6-12 hours; onset 45-90 minutes. Avoid use more than once per 24 hours. Nausea is dose-dependent — start low and titrate. Taking with anti-nausea medication can help.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
FDA-approved route; inject 30-90 minutes before sexual activity; abdomen preferred
Nasal Moderate
Nasal spray formulation (research use); variable bioavailability; faster onset but shorter duration than injection
Sublingual Low
Experimental; lowest bioavailability; not commonly used
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving PT-141:
Male Sexual Enhancement Stack
Enhanced sexual desire, arousal, and emotional bonding
PT-141 drives central melanocortin arousal; Kisspeptin amplifies LH/testosterone release; Oxytocin enhances intimacy and orgasm intensity.
Female Libido Stack
Hypoactive sexual desire disorder (HSDD) management
PT-141 is FDA-approved for HSDD in premenopausal women; Oxytocin nasal spray complements arousal with bonding effects.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 10mg |
|---|---|
| BAC Water | 1-2ml per 10mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution; Vyleesi auto-injector stored at room temperature |
| Shelf Life | 28 days refrigerated after reconstitution |
Need exact syringe measurements?
Amino Acid Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Side Effects & Safety
- Nausea (most common, ~40% of patients)
- Flushing and hyperpigmentation
- Transient blood pressure increase
- Headache
- Vomiting
- Injection site reactions
Synergistic Compounds
The following compounds have been studied alongside PT-141 for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]
- [object Object]